| Title | Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients |
| Authors | Li, Qinqin Zhang, Yuanyuan Cao, Jingjing Zhang, Jingping Nie, Jing Liang, Min Li, Jianping Zhang, Yan Wang, Binyan Huo, Yong Wang, Xiaobin Hou, Fan Fan Xu, Xiping Qin, Xianhui |
| Affiliation | Southern Med Univ, Nanfang Hosp, State Key Lab Organ Failure Res, Natl Clin Res Ctr Kidney Dis,Div Nephrol, Guangzhou 510515, Peoples R China Anhui Med Univ, Inst Biomed, Hefei, Peoples R China Peking Univ First Hosp, Dept Cardiol, Beijing, Peoples R China Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA |
| Keywords | SERUM URIC-ACID POST-HOC ANALYSIS PRIMARY PREVENTION ANGIOTENSIN-II STROKE CHINA REDUCTION THERAPY IMPACT ADULTS |
| Issue Date | Nov-2020 |
| Publisher | ANNALS OF TRANSLATIONAL MEDICINE |
| Abstract | Background: The relationship between blood pressure (BP) control and the risk of new-onset hyperuricemia remains uncertain. We aimed to examine the association between degree of time-averaged on-treatment BP control and new-onset hyperuricemia in general hypertensive patients. Methods: A total of 10,617 hypertensive patients with normal uric acid (UA) concentrations (<357 mu mol/L) at baseline were included from the UA Sub-study of the China Stroke Primary Prevention Trial (CSPPT). Participants were randomized to receive a double-blind daily treatment of enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. BP measurements were taken every three months after randomization. The primary outcome was new-onset hyperuricemia, defined as a UA concentration >= 417 mu mol/L in men or >= 357 mu mol/L in women at the exit visit. Results: Over a median of 4.4 years, 1,664 (15.7%) participants developed new-onset hyperuricemia. Overall, there was a significantly positive association between time-averaged on-treatment diastolic BP (DBP) and new-onset hyperuricemia (per 10 mmHg increment; OR 1.13; 95% CI: 1.02-1.26). Consistently, a significantly higher risk of new-onset hyperuricemia was found in participants with time-averaged on-treatment DBP >= 82.9 mmHg (median) (vs. <82.9 mmHg; 17.3% vs. 14.1%; OR 1.25; 95% CI: 1.10-1.44). Furthermore, the lowest new-onset hyperuricemia risk (12.1%) was found in those with both time-averaged on-treatment SBP (median: 138.3 mmHg) and DBP below the median (P-interaction=0.023). The results were similar for time-averaged DBP during the first 12- or 24-month treatment period, or in the analysis using propensity scores. Furthermore, a non-significant higher risk of new-onset hyperuricemia was observed in participants with time-averaged on-treatment SBP >= 120 mmHg (vs. <120 mmHg; OR 1.61; 95% CI: 0.88-2.97). Conclusions: A tight DBP control of <82.9 mmHg was associated with lower risk of new-onset hyperuricemia among hypertensive patients without hyperuricemia. |
| URI | http://hdl.handle.net/20.500.11897/621744 |
| ISSN | 2305-5839 |
| DOI | 10.21037/atm-20-3017 |
| Indexed | SCI(E) |
| Appears in Collections: | 第一医院 |
